Naman Pharma Private Limited
About Naman Pharma Private Limited
Data last updated:
Naman Pharma Private Limited is a private limited company based in Delhi, India. It operates in the real estate financing segment of the financial services sector. It was incorporated on 24 November 2005 and has been in existence for over 21 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U45201DL2005PTC142940.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Anjesh Teotia and Satish Kumar.
Its last annual general meeting (AGM) was held on 30 September 2023, and its latest financial statements are for the year ended 31 March 2023. The registered office is at 207 Aggarwal Chambers – IV 27 Veer Savarkar Block, Delhi, India – 110092.
As per the financials filed for FY 2023, the company reported a revenue of ₹2.2 Lakh, reflecting significant growth compared to the previous year. For the same year it recorded a net loss of ₹2.12 Lakh (net margin -96.2%) and EBITDA of -₹15,236 (EBITDA margin -6.9%). Revenue has declined at a compounded annual rate (CAGR) of 3% over three years and 2% over five years.
As per MCA filings, the company has open charges of ₹7.01 Cr and satisfied charges of ₹8.53 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered Address207 Aggarwal Chambers – IV 27 Veer Savarkar Block, Delhi, India – 110092
- IndustryFinancial Services, Real Estate Financing
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Financials of Naman Pharma Private Limited FY 2023 filings available
Naman Pharma Private Limited reported revenue of ₹2.2 Lakh (up 1000% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR) of Naman Pharma Private Limited
Revenue rose 1000% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 2%. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Naman Pharma Private Limited
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | ₹2.2 Lakh | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | -₹15,236 | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | -₹2.12 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Naman Pharma Private Limited
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -6.9% | •••• | •••• | •••• | •••• |
| Net Profit Margin | -96.2% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Naman Pharma are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Auditor Details of Naman Pharma Private Limited
Naman Pharma Private Limited is audited by AKHILENDRA SINGH & ASSOCIATES for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| AKHILENDRA SINGH & ASSOCIATES | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Naman Pharma Private Limited
Naman Pharma has 2 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Anjesh Teotia | Director | 20 Apr 2013 | 13 Years 5 Months | Current |
| Satish Kumar Also directs: Kraftstreet Fashion India Private Limited | Director | 20 Apr 2013 | 13 Years 5 Months | Current |
Ownership and Shareholding of Naman Pharma Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Naman Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Aug 2024 | Others | ₹1.8 Cr | Open |
| 02 Feb 2023 | Others | ₹1.43 Cr | Open |
| 24 Jun 2021 | Others | ₹3.78 Cr | Open |
| 10 Oct 2020 | Others | ₹36.9 Lakh | Satisfied |
| 06 Aug 2020 | Others | ₹3 Cr | Satisfied |
Total charge records: 9 View all charges
Employees and EPFO Compliance at Naman Pharma Private Limited
Employment history and EPFO contributions of people linked to Naman Pharma.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Naman Pharma Private Limited
Naman Pharma Private Limited has 9 board changes on record since 2011: 2 appointments and 7 cessations. The latest: Anjesh Teotia ceased to be Additional Director on 29 Jun 2013.
15 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Naman Pharma Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Naman Pharma Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Naman Pharma Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Naman Pharma Private Limited
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Naman Pharma Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Naman Pharma Private Limited
Naman Pharma is an active private limited company based in Delhi, India. The company works in real estate financing, within the financial services industry. It was incorporated on 24 November 2005 (21+ years old) and is registered under CIN U45201DL2005PTC142940.
Naman Pharma reported revenue of ₹2.2 Lakh for FY 2023 (up 1000% YoY).
Naman Pharma has 2 current directors:
- Anjesh Teotia - Director
- Satish Kumar - Director
Naman Pharma reported a net loss of ₹2.12 Lakh (net margin -96.2%) and EBITDA of -₹15,236 (EBITDA margin -6.9%) for FY 2023, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Naman Pharma is -3% over three years and -2% over five years. In the latest year (FY 2023) revenue rose 1000%. CAGR is the steady yearly rate that links the first and the last year.
The CIN (Corporate Identification Number) of Naman Pharma is U45201DL2005PTC142940. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Naman Pharma was incorporated on 24 November 2005, making it 21+ years old. It is registered with the Registrar of Companies, Delhi.
Anjesh Teotia ceased to be Additional Director on 29 Jun 2013. Satish Kumar ceased to be Additional Director on 29 Jun 2013. Prashant Gupta ceased to be Director on 25 Apr 2013. Naman Pharma has 9 board changes on record in total.
The registered office of Naman Pharma is at 207 Aggarwal Chambers – IV 27 Veer Savarkar Block, Delhi, India – 110092.
Naman Pharma has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh.